Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.
about
An outline of necrosome triggersInflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors.Necroinflammation in Kidney Disease.Generation of small molecules to interfere with regulated necrosis.Necroptosis-independent signaling by the RIP kinases in inflammation.Biomarkers for the detection of necroptosis.Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents.The Inflammatory Signal Adaptor RIPK3: Functions Beyond Necroptosis.Complex Pathologic Roles of RIPK1 and RIPK3: Moving Beyond Necroptosis.Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis.Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury.6E11, a highly selective inhibitor of Receptor-Interacting Protein Kinase 1, protects cells against cold hypoxia-reoxygenation injury.Sorafenib inhibits therapeutic induction of necroptosis in acute leukemia cells.Characterization of GSK'963: a structurally distinct, potent and selective inhibitor of RIP1 kinase.CETSA quantitatively verifies in vivo target engagement of novel RIPK1 inhibitors in various biospecimens.Targeting RIPK1,2,3 to combat inflammation.An Inducible Retroviral Expression System for Tandem Affinity Purification Mass-Spectrometry-Based Proteomics Identifies Mixed Lineage Kinase Domain-like Protein (MLKL) as an Heat Shock Protein 90 (HSP90) Client.Drilling into RIP1 biology: what compounds are in your toolkit?Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors.RIPK1-dependent cell death: a novel target of the Aurora kinase inhibitor Tozasertib (VX-680).Immunological consequences of kidney cell death.Repurposing anticancer drugs for targeting necroptosis.Necroptosis in cardiovascular disease - a new therapeutic target.Phenytoin inhibits necroptosis.RIP kinase 1-dependent endothelial necroptosis underlies systemic inflammatory response syndrome.Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations
P2860
Q26751108-CB2F7106-0572-4CDB-AC50-A5ED40C79350Q36084130-BDD70CB4-173A-4478-9BBE-5A3F0D5A4CA3Q38579499-8E9A0C62-371B-4483-975B-72A25E4BDB9DQ38799144-7FA5D8C2-1B70-4648-A878-5589252139A2Q38799149-28E461CF-FFB0-4CCB-A23B-B8E96836C798Q38804928-35D39A5F-1ED0-46CF-9759-8A324B667990Q38939282-0D85A729-6FB2-4B6F-B30E-08161FB8036FQ39077160-A62CCD5D-53FF-42D3-AFFF-BFE20BAF3B32Q39105381-34AE4758-286B-4EEE-9CC8-269DC72214D1Q40132104-28A8B428-92CA-4E52-9B28-76B2F3E7F5F5Q40153668-82A9EBB0-B095-40E0-8495-E7018897B45BQ41919743-453FBD08-348D-48FE-808C-F60D48532D2DQ42366610-4F5EA32F-E413-419B-9C6D-B717FB8AB9E0Q42367954-4DC57528-B6AD-4AE4-A118-6315EC0E5E27Q42376104-B4CA65AB-FFF6-44A5-9002-B8112A63330AQ42551600-73E9F968-5593-4D67-A8EA-2F78B62F9F4CQ42552328-BA5EE256-CED4-4E2E-BC19-9773C3A27E8FQ43167136-F834F932-6B7E-4C21-88A7-A295ADFC7EBFQ48509895-F6219293-0914-467E-A1C2-5772DE97C70AQ49025576-C1321E34-9F8E-4429-B8F3-9ADC55FF0EF9Q49679688-29F031D7-7607-4A7D-A296-2E6B2F4F8D09Q49717299-B33BE53F-12D0-42B9-BFE6-89221A635AADQ52663210-582622F0-A2DA-466D-8EFA-08649EE8C252Q52676399-F5B07C27-240E-4E5D-A7C9-FBEA12CBE4D2Q52718845-05AC353A-18B0-42B0-BF4B-AAC3BA514185Q58699724-A40B5277-2C6A-42A9-8D01-C957B0B978F7
P2860
Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Structure guided design of pot ...... d hybrid inhibitors for RIPK1.
@ast
Structure guided design of pot ...... d hybrid inhibitors for RIPK1.
@en
type
label
Structure guided design of pot ...... d hybrid inhibitors for RIPK1.
@ast
Structure guided design of pot ...... d hybrid inhibitors for RIPK1.
@en
prefLabel
Structure guided design of pot ...... d hybrid inhibitors for RIPK1.
@ast
Structure guided design of pot ...... d hybrid inhibitors for RIPK1.
@en
P2093
P2860
P1433
P1476
Structure guided design of pot ...... ed hybrid inhibitors for RIPK1
@en
P2093
Danish Saleh
Gregory D Cuny
Jenny L Maki
John Bertin
Junying Yuan
Malek Najjar
Peter J Gough
Roshan J Thapa
Saumil Shah
Shoko Nogusa
P2860
P304
P356
10.1016/J.CELREP.2015.02.052
P577
2015-03-01T00:00:00Z